May. 8 at 2:18 PM
$CABA recent history of
$LLYVA , bio investments and acquisitions- last one:
Apr. 2026
Ajax Therapeutics
Lilly agreed to acquire Ajax for up to
$2.3 billion. Lilly explicitly said it was a founding strategic investor in Ajax.
Not CABA-like scientifically, but it is a strong precedent for Lilly converting a strategic investment into an acquisition.
Bottom line - the investment by
$LLY and Bain Capital Life Sciences is a transformational event in the history of
$CABA.
While it doesn’t mean that the clinical trials will succeed, it shows that the biggest names in the industry are getting involved and paying very close attention and if the trials are good, we could be staring at a massive buyout and a 10X or 20 X or more opportunity for the current shareholders who are buying in at this level. Companies like
$LLY and Bain are extraordinarily selective in their investments and very serious $ do due diligence before making them.
Insiders all bought
$CABA and now giants did.
